Dynavax to Report First Quarter 2023 Financial Results and Host Conference Call on May 2, 2023

Rhea-AI Summary

Dynavax Technologies Corporation (Nasdaq: DVAX) will announce its first quarter 2023 financial results on May 2, 2023, after U.S. market close. The company will host a conference call and live audio webcast at 4:30 p.m. ET to discuss these results.

Dynavax is known for its commercial-stage biopharmaceutical products, including the HEPLISAV-B® vaccine for hepatitis B and the CpG 1018® adjuvant used in COVID-19 vaccines. The company's focus includes advancing its adjuvant for various vaccines, including shingles and universal influenza. Further details can be found on their website.

Positive

• Established commercial products: HEPLISAV-B® and CpG 1018® adjuvant.
• Multiple collaborations to develop adjuvanted vaccines for infectious diseases.

Negative

• None.

EMERYVILLE, Calif., April 18, 2023 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a commercial stage biopharmaceutical company developing and commercializing innovative vaccines, will report first quarter 2023 financial results on Tuesday, May 2, 2023, after the U.S. financial markets close.

Dynavax will host a conference call and live audio webcast on Tuesday, May 2, 2023, at 4:30 p.m. ET/1:30 p.m. PT.

The live audio webcast may be accessed through the "Events & Presentations" page on the "Investors" section of the Company's website at https://investors.dynavax.com/events-presentations. A replay of the webcast will be available for 30 days following the live event.

To dial into the call, participants will need to register for the call using the caller registration link. It is recommended that participants dial into the conference call or log into the webcast approximately 10 minutes prior to the call.

About Dynavax
Dynavax is a commercial-stage biopharmaceutical company developing and commercializing innovative vaccines to help protect the world against infectious diseases. The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S., the European Union and Great Britain for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older, and CpG 1018® adjuvant, currently used in multiple adjuvanted COVID-19 vaccines. Dynavax is advancing CpG 1018 adjuvant as a premier vaccine adjuvant with adjuvanted vaccine clinical programs for shingles and Tdap, and through global collaborations, currently focused on adjuvanted vaccines for COVID-19, plague, seasonal influenza and universal influenza. For more information about our marketed products and development pipeline, visit www.dynavax.com and follow Dynavax on LinkedIn and Twitter.

For Investors/Media:
Paul Cox
pcox@dynavax.com
917-754-0207

Nicole Arndt
narndt@dynavax.com
510-665-7264

View original content to download multimedia:https://www.prnewswire.com/news-releases/dynavax-to-report-first-quarter-2023-financial-results-and-host-conference-call-on-may-2-2023-301800900.html

SOURCE Dynavax Technologies

FAQ

When will Dynavax report its first quarter 2023 financial results?

Dynavax will report its first quarter 2023 financial results on May 2, 2023, after U.S. market close.

What products does Dynavax offer?

Dynavax offers HEPLISAV-B® vaccine for hepatitis B and CpG 1018® adjuvant used in COVID-19 vaccines.

How can I listen to the Dynavax conference call?

You can listen to the Dynavax conference call on May 2, 2023, at 4:30 p.m. ET via their website's 'Events & Presentations' page.

What is the focus of Dynavax's vaccine development?

Dynavax focuses on developing innovative vaccines to combat infectious diseases, including collaborations for COVID-19, shingles, and seasonal influenza.